WallStSmart
NVO

Novo Nordisk A/S

NYSE: NVO · HEALTHCARE · DRUG MANUFACTURERS - GENERAL

$42.22
+4.79% today

Updated 2026-04-30

Market cap
$182.60B
P/E ratio
11.40
P/S ratio
0.59x
EPS (TTM)
$3.61
Dividend yield
4.38%
52W range
$35 – $78
Volume
21.0M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Novo Nordisk A/S (NVO) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$42.22
Consensus
$51.00
+20.80%
2030 Target
$1,065.02
+2422.55%
DCF
—
—
29 analysts:
2 Buy7 Hold2 Sell

Management guidance

No specific CEO revenue targets found in available data. Most recent guidance from March 2026 AGM indicates cautious near-term outlook with declining 2026 sales and operating profit expected. Management has not provided explicit 2026-2030 revenue targets in reviewed documents.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$1,775.04
$388.2B Rev × 20x P/S
Base case (2030)
$1,065.02
$388.2B Rev × 12x P/S
Bear case (2030)
$710.02
$388.2B Rev × 8x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)2030 (E)
Revenue$232.3B$290.4B$309.1B$296.9B$315.2B$337.5B$379.0B$388.2B
Revenue growth—25.0%6.4%-3.9%6.1%7.1%13.1%7.0%
EPS$2.74$13.95$23.03$22.12$23.80$25.50$25.80$29.20
P/S ratio———12.0x12.0x12.0x4.0x12.0x
Implied price———$813.56$865.33$924.50$450.71$1,065.02

Catalysts & risks

Growth catalysts
+ Oral Wegovy (semaglutide pill) market expansion vs Eli Lilly's Foundayo - direct competition in $100B+ obesity market by 2030
+ FDA approval of Awiqli (once-weekly insulin icodec) launching H2 2026 - new diabetes franchise with differentiated value
+ GLP-1 market growth from obesity/diabetes expansion - obesity drug market projected $100B+ by 2030 vs ~$50B in 2025
+ Pricing pressure from generics in India, China, Canada, Brazil post-patent expiry - offset by volume in emerging markets
+ Pipeline advancement of LX9851 (licensed from Lexicon) - Phase 1 ongoing, potential next-gen obesity drug
Key risks
- Aggressive competition from Eli Lilly (Mounjaro/Zepbound/Foundayo) with superior efficacy data - pricing power erosion in developed markets
- Patent expiration of semaglutide in India, China, Canada, Brazil, Turkey, South Africa enabling generic competition - revenue decline in 2-3 major markets
- FDA warning letter for failure to report serious adverse events (deaths, suicidal ideation) - potential label changes, liability exposure, patient access restrictions
- US tariff threat (Trump administration: 100% on branded drugs) - margin compression and pricing pressure if tariffs implemented
- Market share loss in Ozempic/Wegovy franchise as oral formulation adoption underperforms vs injectable - GLP-1 market saturation risk

Methodology

Novo Nordisk A/S's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 29 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 6, 2026.